ArticleBreast cancer research : BCR2026
Diagnostic accuracy of FDG-PET-CT to predict axillary lymph node response after neo-adjuvant chemotherapy in lymph node-positive breast cancer patients.
Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn certain cases, some institutions use fluorodeoxyglucose positron emission tomography combined with CT (FDG-PET-CT) scans to assess response to neo-adjuvant chemotherapy (NAC) in lymph node-positive breast cancer (cN+), to determine the extent of surgery and subsequently radiotherapy. In this study, we assessed the diagnostic accuracy of FDG-PET-CT to determine the axillary response to NAC using the histopathology results as the golden standard.
methodsBetween 2016 and 2022, all women with cN+ breast cancer receiving NAC and axillary surgery were retrospectively identified. Patients who underwent pre- and post-NAC staging with FDG-PET-CT were included. Excluded were patients with previous ipsilateral breast cancer, occult breast cancer or bilateral breast cancer. The histopathology lymph node results from surgery were used to calculate the diagnostic accuracy of FDG-PET-CT for detecting axillary lymph node metastases post-NAC.
resultsSeventy-five patients were included. Forty-one patients (55%) had histologically proven axillary metastatic disease at the response evaluation after NAC, although FDG-PET positivity was only apparent in nine of these patients. There was a sensitivity of 22% (95% CI 11–38%) for FDG-PET-CT in detecting axillary lymph node metastases after NAC and a specificity of 94% (95% CI 80–99%). The positive predictive value was 82% (95% CI 48–98%) and the negative predictive value (NPV) was 50% (95% CI 37–63%).
conclusionsFDG-PET-CT scans have a low sensitivity and NPV to identify residual disease after NAC, indicating that these scans are unlikely to aid in decision making. Omission of post-NAC FDG-PET-CT should be considered in lymph node response evaluation unless other clinical indications with no other alternative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.